# US 2006/0156423 A1 · Method of screening antiobesity agents and animal model of obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0156423 A1
- Document ID: US20060156423A1
- Status: Published application
- Kind: A1
- Application number: 10/551,964
- Filed: 2004-06-03
- Published: 2006-07-13
- Earliest claimed: 2003-06-06
- Inventors: Kunio Yasunaga
- Web page: https://patentgrep.com/patent/US20060156423A1

## CPC

- A01K 67/0276: Knock-out vertebrates
- C07K 14/515: Angiogenesic factors; Angiogenin
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A01K 2267/0306: Animal model for genetic diseases
- A01K 2267/0362: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2830/00: Vector systems having a special element relevant for transcription
- C12N 2830/85: mammalian
- C12N 2840/203: having an IRES
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A promoter for an angiopoietin-related growth factor (AGF), a vector comprising the promoter, a transformant comprising the promoter, and a method for screening an antiobesity agent, an antidiabetic agent, and/or a hypolipidemic agent by using the transformant, are disclosed. Further, an AGF knockout animal useful as an animal model for obesity, diabetes, and/or hyperlipemia is disclosed. Furthermore, an AGF transgenic animal useful for identification of a target molecule in a new drug development and/or a therapeutic agent for obesity, diabetes, and/or hyperlipemia is disclosed.

## Claims

### Claim 1

(a) A DNA exhibiting a promoter activity for an angiopoietin-related growth factor, and consisting of a nucleotide sequence in which 1 to 10 nucleotides are substituted, deleted, added, and/or inserted in the nucleotide sequence consisting of nucleotides 2705-3001 of SEQ ID NO: 1, or
(b) a DNA exhibiting a promoter activity for an angiopoietin-related growth factor, and consisting of a nucleotide sequence having a 90% or more homology with that consisting of nucleotides 2705-3001 of SEQ ID NO: 1.

### Claim 2

A DNA consisting of the nucleotide sequence consisting of nucleotides 2705-3001 of SEQ ID NO: 1.

### Claim 3 (depends on 1)

A recombinant vector characterized by comprising the DNA according to claim 1, and exhibiting a promoter activity for an angiopoietin-related growth factor.

### Claim 4 (depends on 1)

A transformant characterized by comprising the DNA according to claim 1, and exhibiting a promoter activity for an angiopoietin-related growth factor.

### Claim 5 (depends on 4)

A method for screening an antiobesity agent, an antidiabetic agent, and/or a hypolipidemic agent, characterized by comprising the steps of:
i) bringing a substance to be tested into contact with the transformant according to claim 4, and
ii) measuring a promoter activity for an angiopoietin-related growth factor and analyzing a test substance dependent change in the promoter activity.

### Claim 6 (depends on 5)

The screening method according to claim 5, wherein the transformant contains a reporter gene located downstream of the DNA and the promoter activity for an angiopoietin-related growth factor is measured by analyzing an expression of the reporter gene.

### Claim 7

A nonhuman knockout animal characterized in that a polynucleotide encoding an angiopoietin-related growth factor is functionally deficient on a chromosome.

### Claim 8

A nonhuman transgenic animal which is a nonhuman animal or an offspring animal thereof obtained by ontogenesis from totipotent cells in which a polynucleotide is introduced together with a CAG promoter, wherein the polynucleotide is carried on a chromosome, a polypeptide encoded by the polynucleotide is expressed in a somatic cell, and the polypeptide is selected from the group consisting of:
(a) a polypeptide exhibiting an activity of suppressing an increase in body weight, and comprising an amino acid sequence consisting of amino acids 1-450 of SEQ ID NO: 3 or amino acids 1-433 of SEQ ID NO: 5,
(b) a polypeptide exhibiting an activity of suppressing an increase in body weight, and comprising an amino acid sequence in which 1 to 10 amino acids are substituted, deleted, and/or inserted in an amino acid sequence consisting of amino acids 1-450 of SEQ ID NO: 3 or amino acids 1-433 of SEQ ID NO: 5,
(c) a polypeptide exhibiting an activity of suppressing an increase in body weight, and encoded by a DNA which hybridizes under stringent conditions to a DNA encoding an amino acid sequence consisting of amino acids 1-450 of SEQ ID NO: 3 or amino acids 1-433 of SEQ ID NO: 5, and
(d) a polypeptide exhibiting an activity of suppressing an increase in body weight, and comprising an amino acid sequence having a 95% or more homology with that consisting of amino acids 1-450 of SEQ ID NO: 3 or amino acids 1-433 of SEQ ID NO: 5.
